



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

**Correction to *Lancet Respir Med* 2021;  
published online Sept 1.  
[https://doi.org/10.1016/  
S2213-2600\(21\)00331-3](https://doi.org/10.1016/S2213-2600(21)00331-3)**

Marconi VC, Ramanan AV, de Bono S, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. *Lancet Respir Med* 2021; published online Sept 1. [https://doi.org/10.1016/S2213-2600\(21\)00331-3](https://doi.org/10.1016/S2213-2600(21)00331-3)—In this Article, in figure 2A the number at risk for the baricitinib group at Day 14 should be 684. This correction has been made to the online version as of Sept 8, 2021 and will be made to the printed version.

**Correction to  
*Lancet Respir Med* 2021;  
9: 1130–40**

Hinks TSC, Cureton L, Knight R, et al. Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial. *Lancet Respir Med* 2021; **9**: 1130–40—The appendix of this Article has been corrected and the data in the following Results text is now corrected: "...while systemic corticosteroids were co-prescribed in 13 (9%) receiving azithromycin". These corrections have been made to the online version as of Sept 2, 2021, and will be made to the printed version.



Published Online  
September 8, 2021  
[https://doi.org/10.1016/  
S2213-2600\(21\)00410-0](https://doi.org/10.1016/S2213-2600(21)00410-0)



Published Online  
September 2, 2021  
[http://dx.doi.org/10.1016/  
S2213-2600\(21\)00374-X](http://dx.doi.org/10.1016/S2213-2600(21)00374-X)